Leadership Team

Steven Nichtberger, M.D.

President, Chief Executive Officer, and Co-Founder

Dr. Nichtberger has served as Chief Executive Officer, President, and Chairman of Cabaletta Bio since its founding in 2017. He is also a senior fellow and adjunct professor at the Wharton School of the University of Pennsylvania and a member of the executive committee of the board of governors of Main Line Health, a not-for-profit regional health system. In 2008, his leadership as founding CEO of Tengion (2004-2011) was recognized nationally with the prestigious Ernst & Young Entrepreneur of the Year® award for emerging companies. Earlier in his career, Dr. Nichtberger served as the head of global marketing for Merck and in various commercial operating roles at the company from 1995 to 2003. He has previously served as a member of the boards of directors of the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio, (including as chairman), and Biotechnology Industry Organization. From 2008-2019 he was a member of the board of overseers for the School of Arts & Sciences at the University of Pennsylvania. Dr. Nichtberger received his M.D. from the State University of New York at Buffalo, his B.S. from The Wharton School and his B.A. from the College of Arts & Sciences, at the University of Pennsylvania. He completed internship, residency, and fellowship in the Department of Medicine and the Division of Cardiology of the Mount Sinai Medical Center in New York.

Samik Basu, M.D.

Chief Scientific Officer

Dr. Basu joined Cabaletta in December 2019 and was most recently Vice President of Preclinical Research and Translational Medicine before assuming his new role as Chief Scientific Officer. Prior to joining Cabaletta, Dr. Basu was Head of Translational Sciences (Medicine) at Adaptimmune Therapeutics, plc, where he led research efforts focused on understanding the mechanisms of resistance and response to T-cell receptor based adoptive immunotherapies to inform next generation approaches and clinical strategies. Before that, Dr. Basu co-led preclinical development efforts for Keytruda® (pembrolizumab) at Merck Research Laboratories. He is a physician-scientist with 17 years of industry and academic experience in adoptive immunotherapy, translational research, autoimmunity, and tumor immunology with prior roles at the National Institutes of Health, Albert Einstein College of Medicine, and the University of Pennsylvania. Dr. Basu holds an M.D. from Temple University and completed residency training in Clinical Pathology.

Gwendolyn Binder, Ph.D.

President, Science & Technology

Dr. Binder joined Cabaletta Bio in February 2019 as one of Cabaletta first employees and established the preclinical, translational, manufacturing and quality organizations. As President of Science and Technology, Dr. Binder is responsible for establishing and executing strategies in research and manufacturing to deliver competitive and transformative cellular therapeutics for patients with autoimmune disease.   In addition to her position at Cabaletta Bio, she serves on the Board of Directors of Instil Bio, a company developing novel cancer immunotherapies, and as a member of the Scientific Advisory Board for Immatics, which is a publicly traded company developing engineered T cell immunotherapy for cancer.  Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she established early clinical, translational research and manufacturing functions in the U.S. arm of the company, including providing oversight on the build out of a commercial scale cell therapy manufacturing facility, and ultimately transitioned to lead the research team to focus on prioritizing next generation products and novel targets in early clinical development. Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she where she progressed multiple Investigational New Drug (“IND”) applications for novel engineered T-cell therapies in human immunodeficiency (“HIV”) and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah®), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. Prior to that, she served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg Maryland where she supported the development of the first clinical lentiviral vector used in humans.  Dr. Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, USA where she earned in Ph.D. in Cellular and Molecular Medicine in 2002.  She has authored over 30 publications in the field, including top international journals such as “Science”, and “Nature Medicine”.   She is a recognized leader in the biotechnology sector for the translational and clinical advancement of novel T cell therapies for patients with serious diseases. 

David J. Chang, M.D., M.P.H, FACR

Chief Medical Officer

Dr. Chang joined Cabaletta in June 2019 as Chief Medical Officer. Previously, he was Senior Vice President and Head, Inflammation, Autoimmunity & Neuroscience, or IA&NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&NS. Prior to AstraZeneca, Dr. Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. While at AstraZeneca and GlaxoSmithKline, he provided leadership in driving the clinical development and registration of the only two products approved for systemic lupus erythematosus in the US in over 60 years. From 1997-2022, Dr. Chang was a faculty member in the Division of Rheumatology at the Perelman School of Medicine at the University of Pennsylvania. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University, and his B.S. from Yale University. Dr. Chang completed his internship and residency in internal medicine at the New York Hospital—Cornell University Medical Center and fellowship in Rheumatology at the Hospital for Special Surgery—Cornell University Medical Center. He is a Fellow of the American College of Rheumatology.

Arun Das, M.D.

Chief Business Officer

Dr. Das joined Cabaletta in July 2019 and was most recently Executive Director of New Product Planning and Business Development before assuming his new role as Chief Business Officer. He is also a Lecturer in the Health Care Management Department at the Wharton School of the University of Pennsylvania. Prior to joining Cabaletta, Dr. Das was a resident physician in General Pediatrics at the Children’s Hospital of Philadelphia. Previously, he was an investment banking analyst within the healthcare group at Goldman Sachs. In addition, Dr. Das has spent multiple years consulting in business development and operations for several start-ups in the biotechnology space. Dr. Das received his M.D. from Johns Hopkins University School of Medicine and a B.A. and B.S. dual degree from the University of Pennsylvania.

Michael Gerard

General Counsel

Mr. Gerard joined Cabaletta in September 2021 as General Counsel. Before joining Cabaletta, he served as Associate General Counsel at Spark Therapeutics, a member of the Roche Group. While at Spark, he supported the global gene therapy Manufacturing, Business Development, Technical Development, Supply Chain, Quality, Alliance Management, Real Estate, IT and Facilities teams. Prior to joining Spark, he worked in roles of increasing responsibility at Sandoz, a division of the Novartis Group, achieving the position of Executive Director, Associate General Counsel, BD&L, Strategy and Portfolio. Mr. Gerard also worked as Assistant General Counsel at Aramark. He began his legal career at K&L Gates LLP, later joining Morrison & Foerster LLP before assuming his roles as in-house counsel. Mr. Gerard holds a J.D. from Cornell Law School and received his B.A. in Political Science from the University of Michigan.

Heather Harte-Hall

Chief Compliance Officer

Ms. Harte-Hall joined Cabaletta in March 2019 and was most recently Vice President of Quality and Compliance before assuming her new role as Chief Compliance Officer. Previously, she was Head of Clinical Quality and Compliance at Adaptimmune Therapeutics, plc, where she built a compliance program and helped establish a culture of integrity to drive ethical behavior in the management and conduct of clinical trials. Ms. Harte-Hall developed and implemented quality and compliance programs focusing on risk management and compliance functions to improve activities such as regulatory monitoring, auditing, and managing alignment with policies, procedures and controls. Ms. Harte-Hall has over 15 years of experience in pharmaceutical and healthcare management and has held various positions in quality and compliance at Centocor Biotech, Inc., Wyeth, LLC and Pfizer Inc. She currently serves as a committee member for the Alliance for Regenerative Medicine (ARM) Accelerator Group and a member of the Society of Corporate Compliance and Ethics (SCCE). Ms. Harte-Hall holds a Master of Science in Psychology from Capella University and B.A. in Business Administration from St. Leo University.

Anup Marda

Chief Financial Officer

Mr. Marda joined Cabaletta in January 2019 as Chief Financial Officer. From April 2001 to January 2019, Mr. Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning & Analysis, and, from 2014 to 2018, as Head of Finance, R&D Operations and Head of Finance, R&D Portfolio Management and Global Medical. Prior to this, Mr. Marda was Executive Director, U.S. Pharmaceuticals from 2012 to 2014, and Assistant Treasurer, Capital Markets from 2008 to 2012. Mr. Marda received his M.B.A. from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay.

Nicolette Sherman

Chief Human Resources Officer

Ms. Sherman joined Cabaletta in November 2024 as Chief Human Resources Officer. Ms. Sherman brings almost two decades of experience leading human resources and organizational functions at biotechnology and pharmaceutical companies. Prior to joining Cabaletta, Ms. Sherman was CHRO at Certara, where she developed and implemented a business-aligned people strategy that innovated talent management, strengthened workforce planning, and fostered a future-ready culture. Before that, she served as the first CHRO at Oyster Point Pharma, Inc, preparing the organization for commercial launch. Earlier in her career, Ms. Sherman served in multiple roles of increasing responsibility at Sanofi, Schering-Plough, AT&T and Prudential. Ms. Sherman received Master’s degrees in Human Resource Management from Rutgers University and Political Science from the University of Delaware, in addition to a B.A. in Government from Lehigh University.

Gerwin Winter, PharmD, MBA

Head of International

Mr. Winter joined Cabaletta in October 2024 as Senior Vice President and Head of International to lead a focused team to expand our clinical development in Europe. Mr. Winter has nearly three decades of experience building and leading global clinical and commercial operations teams to bring innovative medicines closer to patients. Prior to joining Cabaletta, Mr. Winter was Senior Vice President, Head of Europe at BeiGene from inception to launch of Brukinsa® in 26 markets. Before that, Mr. Winter was Senior Vice President and Head of Europe for Portola Pharmaceuticals, building European operations to successfully launch Ondexxya® and leading the team through its acquisition by Alexion in 2020. Earlier in his career, Mr. Winter served in multiple positions of increasing responsibility at Bristol-Myers Squibb for launches in rheumatology for Orencia® and hematology for Sprycel® and as General Manager Germany for Celgene for multiple launches in hematology, oncology, and rheumatology. Mr. Winter received a PharmD in Pharmacy from the University of Munich, Germany and an M.B.A. in General Management from CEDEP at INSEAD University of Fontainebleau, France.

Sarah Yuan, Ph.D.

Chief Technology Officer

Dr. Yuan joined Cabaletta in June 2024 as Chief Technology Officer to oversee Technical Development, Manufacturing, Supply Chain and CMC Strategy organizations. Dr. Yuan brings more than 20 years of CMC experience from a broad range of leading biopharmaceutical companies. Prior to joining Cabaletta, Dr. Yuan was Chief Technical Operations Officer at Sigilon Therapeutics, a wholly owned subsidiary of Eli Lilly & Co, where she led the CMC efforts to develop a novel cell therapy based on Sigilon’s Shielded Living Therapeutics^TM platform. Before that, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio, where she was instrumental in getting three cell therapy products approved, in addition to advancing a preclinical product through IND clearance. Earlier in her career, Dr. Yuan held various leadership roles in External Manufacturing, Technical Development, Manufacturing Sciences and CMC Strategies at Sanofi, Bioverativ, Biogen, Agenus (formerly known as Antigenics) and Millipore. Dr. Yuan received her Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, and B.S. from University of California, Berkeley.